PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Esthesioneuroblastoma

Drugs in development · updated 30 October 2026

Esthesioneuroblastoma: drugs in development

Rare diseasePrevalence <1 / 1 000 000 according to Orphanet · ORPHA:1957

As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for esthesioneuroblastoma. One is experimental, that is not yet approved in the United States.

6Active trials
1Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ZanzalintinibXL092II1NCT07527169

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CisplatinCis Platinum, CisplatineII1NCT06255210
CyclophosphamideCyclophosphamid, CytoxanII1NCT06255210
EnasidenibAG-221, Idhifa®II1NCT06176989
EtoposideAvopef®, Etopophos Preservative Free®II1NCT06255210
GemcitabineGemcitabin, GemzarII1NCT06255210
LutatheraLutetium Lu 177 Dotatate, 177Lu-DOTATATEI–II1NCT06607692
OlaparibAZD2281, Lynparza®I–II1NCT06607692
TarlatamabImdelltra®, Imdylltra®I–II1NCT06814496
68Ga-DOTATATEGallium 68 Dotatate, Gallium Ga 68-DOTATATEI1NCT06479811

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018304 “Esthesioneuroblastoma, Olfactory”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch